GB1527605A - Insulin preparation for intranasal administration - Google Patents

Insulin preparation for intranasal administration

Info

Publication number
GB1527605A
GB1527605A GB34576/75A GB3457675A GB1527605A GB 1527605 A GB1527605 A GB 1527605A GB 34576/75 A GB34576/75 A GB 34576/75A GB 3457675 A GB3457675 A GB 3457675A GB 1527605 A GB1527605 A GB 1527605A
Authority
GB
United Kingdom
Prior art keywords
insulin
preparation
weight
agents
intranasal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB34576/75A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to GB34576/75A priority Critical patent/GB1527605A/en
Priority to DE19762620446 priority patent/DE2620446A1/en
Priority to BE167070A priority patent/BE841871A/en
Priority to FR7614707A priority patent/FR2321275A1/en
Priority to JP51055965A priority patent/JPS6030651B2/en
Publication of GB1527605A publication Critical patent/GB1527605A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1527605 Intranasal insulin compositions containing surface-active agents TAKEDA YAKUHIN KOGYO KK 12 May 1976 [20 Aug 1975] 34576/75 Heading A5B An aqueous insulin preparation for intranasal application for absorption through the nasal mucous membranes, comprises water, 0.1 to 10% by weight of insulin, and 0.1 to 20% by weight of a surface active agent selected from non-ionic surfactants, amphoteric surfactants, anionic surfactants, surfactin (a bacterial lipopeptide), bile salts and saponins, the preparation having a pH value above 4.7 and not containing a dialkyl sulphoxide. The pH is preferably from over 4.7 to 9.0, and is best administered as a nasal spray. It may also contain agents (e.g. salts) for adjusting the toxicity to be isotonic with body fluids, antiseptics, preservatives and buffering agents.
GB34576/75A 1975-08-20 1975-08-20 Insulin preparation for intranasal administration Expired GB1527605A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GB34576/75A GB1527605A (en) 1975-08-20 1975-08-20 Insulin preparation for intranasal administration
DE19762620446 DE2620446A1 (en) 1975-08-20 1976-05-08 Aqueous INSULIN PREPARATION
BE167070A BE841871A (en) 1975-08-20 1976-05-14 NEW INSULIN PREPARATION
FR7614707A FR2321275A1 (en) 1975-08-20 1976-05-14 INSULIN PREPARATION FOR NASAL ADMINISTRATION
JP51055965A JPS6030651B2 (en) 1975-08-20 1976-05-14 Insulin preparations for nasal administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB34576/75A GB1527605A (en) 1975-08-20 1975-08-20 Insulin preparation for intranasal administration

Publications (1)

Publication Number Publication Date
GB1527605A true GB1527605A (en) 1978-10-04

Family

ID=10367351

Family Applications (1)

Application Number Title Priority Date Filing Date
GB34576/75A Expired GB1527605A (en) 1975-08-20 1975-08-20 Insulin preparation for intranasal administration

Country Status (5)

Country Link
JP (1) JPS6030651B2 (en)
BE (1) BE841871A (en)
DE (1) DE2620446A1 (en)
FR (1) FR2321275A1 (en)
GB (1) GB1527605A (en)

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
EP0115627B1 (en) * 1982-12-29 1987-04-01 Armour Pharmaceutical Company Enhancement of intranasal absorption of calcitonin by formulation with surfactants
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
WO1988004556A1 (en) * 1986-12-16 1988-06-30 Novo Industri A/S Nasal formulations and a process for preparation thereof
US4772585A (en) * 1984-08-08 1988-09-20 Survival Technology, Inc. Protein thrombolytic agent with absorption enhancing agent
AU584184B2 (en) * 1985-04-15 1989-05-18 Eli Lilly And Company An improved method for administering insulin
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5053389A (en) * 1986-04-18 1991-10-01 Per Balschmidt Insulin preparation for non-parenteral administration
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5338837A (en) * 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
US5506203A (en) * 1993-06-24 1996-04-09 Ab Astra Systemic administration of a therapeutic preparation
US5518998A (en) * 1993-06-24 1996-05-21 Ab Astra Therapeutic preparation for inhalation
US5635612A (en) * 1993-02-23 1997-06-03 The Trustees Of Princeton University Method of forming multiple glycosidic linkages in a single step
US5643868A (en) * 1990-10-10 1997-07-01 Autoimmune, Inc. Method of treating or preventing type 1 diabetes by oral administration of insulin
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5902789A (en) * 1986-04-23 1999-05-11 Fisons Corporation Nasal administration of drugs
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US5997848A (en) 1994-03-07 1999-12-07 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6194393B1 (en) * 1993-02-23 2001-02-27 The Trustees Of Princeton University Solution and solid-phase formation of glycosidic linkages
EP0689052B1 (en) * 1994-06-24 2001-09-26 Sysmex Corporation Insulin standard solution
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US7476652B2 (en) * 2002-06-18 2009-01-13 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US7696162B2 (en) 2001-03-23 2010-04-13 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US7744925B2 (en) 1994-12-02 2010-06-29 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US8273330B2 (en) 2002-04-25 2012-09-25 Nektar Therapeutics Particulate materials
US8337895B2 (en) 2000-06-30 2012-12-25 Novartis Ag Spray drying process control of drying kinetics
US8802149B2 (en) 1996-12-31 2014-08-12 Novartis Pharma Ag Systems and processes for spray drying hydrophobic and hydrophilic components
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5145405A (en) * 1974-10-16 1976-04-17 Unyusho Kowan Gijutsu Kenkyush JIBAN KAIRYOKOHO
JPS53115509A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Method of changing weak ground into stable ground
JPS53115510A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Support structure made by hardening weak soil
DE2917535C2 (en) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Insulin solutions resistant to denaturation
EP0083619A1 (en) * 1981-07-17 1983-07-20 Nordisk Insulinlaboratorium A stable aqueous, therapeutic insulin preparation and a process for preparing it
CH657779A5 (en) * 1982-10-05 1986-09-30 Sandoz Ag GALENIC COMPOSITIONS CONTAINING CALCITONIN.
EP0111841B1 (en) * 1982-12-10 1987-05-06 Syntex (U.S.A.) Inc. Lhrh preparations for intranasal administration
DE3443877A1 (en) * 1984-06-09 1985-12-12 Hoechst Ag Insulin preparations, process for their preparation, and their use
IL78425A (en) * 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
JPH0713372B2 (en) * 1989-02-14 1995-02-15 鹿島建設株式会社 Construction method of structure foundation in sandy soil layer
JPH04126437U (en) * 1991-05-10 1992-11-18 八木アンテナ株式会社 optical receiver
CA2206782C (en) 1994-12-22 2007-04-03 Astra Aktiebolag Aerosol drug formulations
WO2012096276A1 (en) * 2011-01-13 2012-07-19 株式会社カネカ Percutaneous absorption promoter and external skin preparation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62232C (en) * 1900-01-01
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Cited By (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0115627B1 (en) * 1982-12-29 1987-04-01 Armour Pharmaceutical Company Enhancement of intranasal absorption of calcitonin by formulation with surfactants
EP0122036A1 (en) * 1983-03-09 1984-10-17 Teijin Limited Powdery pharmaceutical composition for nasal administration
AU580262B2 (en) * 1983-06-06 1989-01-12 Martin C. Carey Drug administration
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4772585A (en) * 1984-08-08 1988-09-20 Survival Technology, Inc. Protein thrombolytic agent with absorption enhancing agent
AU584184B2 (en) * 1985-04-15 1989-05-18 Eli Lilly And Company An improved method for administering insulin
US5053389A (en) * 1986-04-18 1991-10-01 Per Balschmidt Insulin preparation for non-parenteral administration
US5902789A (en) * 1986-04-23 1999-05-11 Fisons Corporation Nasal administration of drugs
WO1988004556A1 (en) * 1986-12-16 1988-06-30 Novo Industri A/S Nasal formulations and a process for preparation thereof
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5643868A (en) * 1990-10-10 1997-07-01 Autoimmune, Inc. Method of treating or preventing type 1 diabetes by oral administration of insulin
US5843886A (en) * 1990-10-10 1998-12-01 Autoimmune, Inc. Method of treating or preventing Type 1 diabetes by oral administration of insulin
US6703361B2 (en) 1990-10-10 2004-03-09 Autoimmune Inc. Method of treating or preventing Type 1 diabetes by oral administration of insulin
US5858968A (en) * 1990-10-10 1999-01-12 Autoimmune Inc. Method of treating or preventing type 1 diabetes by oral administration of insulin
US5455335A (en) * 1991-12-13 1995-10-03 The Trustees Of Princeton University Pharmaceutical compositions and methods of transporting compounds across biological membrane
US5571795A (en) * 1991-12-13 1996-11-05 The Trustees Of Princeton University Derivative-compound-conjugates and pharmaceutical compositions comprising same
US5338837A (en) * 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6797258B2 (en) 1992-07-08 2004-09-28 Nektar Therapeutics Compositions and methods for the pulmonary delivery of aerosolized macromolecules
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US5635612A (en) * 1993-02-23 1997-06-03 The Trustees Of Princeton University Method of forming multiple glycosidic linkages in a single step
US6194393B1 (en) * 1993-02-23 2001-02-27 The Trustees Of Princeton University Solution and solid-phase formation of glycosidic linkages
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5518998A (en) * 1993-06-24 1996-05-21 Ab Astra Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5506203A (en) * 1993-06-24 1996-04-09 Ab Astra Systemic administration of a therapeutic preparation
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6306440B1 (en) 1993-06-24 2001-10-23 Astrazeneca Ab Therapeutic preparation for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6592904B2 (en) 1994-03-07 2003-07-15 Inhale Therapeutic Systems, Inc. Dispersible macromolecule compositions and methods for their preparation and use
US6737045B2 (en) 1994-03-07 2004-05-18 Nektar Therapeutics Methods and compositions for the pulmonary delivery insulin
US6423344B1 (en) 1994-03-07 2002-07-23 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
EP2036541A1 (en) 1994-03-07 2009-03-18 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US5997848A (en) 1994-03-07 1999-12-07 Inhale Therapeutic Systems Methods and compositions for pulmonary delivery of insulin
US6685967B1 (en) 1994-03-07 2004-02-03 Nektar Therapeutics Methods and compositions for pulmonary delivery of insulin
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US8173168B2 (en) 1994-03-07 2012-05-08 Novartis Pharma Ag Dispersible macromolecule compositions and methods for their preparation and use
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
EP0689052B1 (en) * 1994-06-24 2001-09-26 Sysmex Corporation Insulin standard solution
US7785631B2 (en) 1994-12-02 2010-08-31 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7780991B2 (en) 1994-12-02 2010-08-24 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US7744925B2 (en) 1994-12-02 2010-06-29 Quadrant Drug Delivery Limited Solid dose delivery vehicle and methods of making same
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5993783A (en) * 1995-04-14 1999-11-30 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder α1-antitrypsin
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US8802149B2 (en) 1996-12-31 2014-08-12 Novartis Pharma Ag Systems and processes for spray drying hydrophobic and hydrophilic components
US8337895B2 (en) 2000-06-30 2012-12-25 Novartis Ag Spray drying process control of drying kinetics
US7696162B2 (en) 2001-03-23 2010-04-13 Sanofi-Aventis Deutschland Gmbh Zinc-free and low-zinc insulin preparations having improved stability
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US8273330B2 (en) 2002-04-25 2012-09-25 Nektar Therapeutics Particulate materials
US9700529B2 (en) 2002-05-03 2017-07-11 Nektar Therapeutics Particulate materials
US10945972B2 (en) 2002-05-03 2021-03-16 Nektar Therapeutics Particulate materials
US10188614B2 (en) 2002-05-03 2019-01-29 Nektar Therapeutics Particulate materials
US7476652B2 (en) * 2002-06-18 2009-01-13 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
AU2003238471B2 (en) * 2002-06-18 2009-02-19 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations with improved stability
US7713930B2 (en) 2002-06-18 2010-05-11 Sanofi-Aventis Deutschland Gmbh Acidic insulin preparations having improved stability
US9526764B2 (en) 2008-10-17 2016-12-27 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1-agonist
US10117909B2 (en) 2008-10-17 2018-11-06 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a GLP-1 agonist
US10028910B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1-agonist and methionine
US10029011B2 (en) 2009-11-13 2018-07-24 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
US9707176B2 (en) 2009-11-13 2017-07-18 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
US9981013B2 (en) 2010-08-30 2018-05-29 Sanofi-Aventis Deutschland Gmbh Use of AVE0010 for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9987332B2 (en) 2011-09-01 2018-06-05 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
US10434147B2 (en) 2015-03-13 2019-10-08 Sanofi-Aventis Deutschland Gmbh Treatment type 2 diabetes mellitus patients
US10159713B2 (en) 2015-03-18 2018-12-25 Sanofi-Aventis Deutschland Gmbh Treatment of type 2 diabetes mellitus patients

Also Published As

Publication number Publication date
JPS5225013A (en) 1977-02-24
JPS6030651B2 (en) 1985-07-17
FR2321275A1 (en) 1977-03-18
FR2321275B1 (en) 1979-04-13
BE841871A (en) 1976-11-16
DE2620446A1 (en) 1977-03-03

Similar Documents

Publication Publication Date Title
GB1527605A (en) Insulin preparation for intranasal administration
US4933169A (en) Antiviral inhalation therapy
DE69313865D1 (en) TASTE-MASKING COMPOSITIONS OF RANITIDIN
MY122060A (en) Highly concentrated aqueous glyphosate compositions
EP0225130A3 (en) Liposome composition
ES8607721A1 (en) Solubilization of ivermectin in water.
NO308393B1 (en) Antibacterial oral hygiene preparation
PE28397A1 (en) NON-INORGANIC SALINE SOLUTIONS FOR ENDONASAL ADMINISTRATION
JPS56123910A (en) Dentifrice composition
MY104534A (en) Cleaning composition.
GB1399834A (en) Pharmaceutical compositions
JPS54134711A (en) Shampoo composition
AU4892493A (en) Aqueous dispersible concentrate containing linuron as active ingredient
GB915816A (en) Acidic cosmetic preparations and processes for their manufacture
KR910700002A (en) New concentrated aqueous emulsion, method for its preparation and use as pesticide
JPH0717863A (en) Pranoprofen ophthalmic preparation
AU629445B2 (en) Improvements in or relating to topical compositions containing 1 alpha 25-dihydroxycholecalciferol
National Toxicology Program Carcinogenesis bioassay of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (CAS No. 1746-01-6) in Swiss-Webster mice (dermal study)
JPS55157509A (en) Ultraviolet ray intercepting agent safe to skin
GB1165997A (en) Halogen-Containing Phosphorothioate Esters and Insecticidal Compositions Containing them
JPS5762218A (en) Ophthalmic solution
ES8304429A1 (en) Levonantradol and N-methyllevonantradol formulations.
ATE77238T1 (en) PRIMYCIN SOLUTIONS.
JPS56125305A (en) Creamy or milky lotion cosmetic
US2115848A (en) Ephedrine composition

Legal Events

Date Code Title Description
PS Patent sealed
704A Declaration that licence is not available as of right for an excepted use (par. 4a/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19920512